Real-time
Euronext Bruxelles
05:11:21 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
95.2
EUR
|
-0.21%
|
|
+2.92%
|
+32.78%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,704
|
2,827
|
3,677
|
4,019
|
3,151
|
3,192
|
Enterprise Value (EV)
1 |
2,846
|
2,913
|
3,709
|
4,024
|
3,198
|
3,270
|
P/E ratio
|
9.48
x
|
9.96
x
|
14.1
x
|
10.6
x
|
37
x
|
36.2
x
|
Yield
|
0.92%
|
0.98%
|
0.82%
|
0.83%
|
1.21%
|
1.35%
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
386,638,687,032
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
392,371,878,420
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,487
x
|
-1,888
x
|
-2,405
x
|
-8,116
x
|
-1,352
x
|
-1,173
x
|
FCF Yield
|
-0.07%
|
-0.05%
|
-0.04%
|
-0.01%
|
-0.07%
|
-0.09%
|
Price to Book
|
1.16
x
|
1.06
x
|
1.32
x
|
1.24
x
|
1.8
x
|
1.78
x
|
Nbr of stocks (in thousands)
|
44,549
|
44,513
|
44,513
|
44,513
|
44,513
|
44,513
|
Reference price
2 |
60.70
|
63.50
|
82.60
|
90.30
|
70.80
|
71.70
|
Announcement Date
|
2/28/19
|
2/20/20
|
2/27/21
|
2/26/22
|
3/18/23
|
3/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
0.008151
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.825
|
-0.993
|
-2.249
|
-1.357
|
-1.823
|
-2.079
|
Operating Margin
|
-
|
-
|
-
|
-
|
-22,362.69%
|
-
|
Earnings before Tax (EBT)
1 |
285.2
|
283.7
|
260.5
|
380.1
|
85.17
|
88.15
|
Net income
1 |
285.2
|
283.7
|
260.5
|
380.1
|
85.17
|
88.15
|
Net margin
|
-
|
-
|
-
|
-
|
1,044,901.09%
|
-
|
EPS
2 |
6.401
|
6.374
|
5.853
|
8.539
|
1.913
|
1.980
|
Free Cash Flow
1 |
-1.914
|
-1.543
|
-1.542
|
-0.4958
|
-2.366
|
-2.789
|
FCF margin
|
-
|
-
|
-
|
-
|
-29,023.51%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.5600
|
0.6200
|
0.6800
|
0.7500
|
0.8600
|
0.9700
|
Announcement Date
|
2/28/19
|
2/20/20
|
2/27/21
|
2/26/22
|
3/18/23
|
3/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
142
|
86.5
|
32.6
|
4.14
|
46.7
|
78.6
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.91
|
-1.54
|
-1.54
|
-0.5
|
-2.37
|
-2.79
|
ROE (net income / shareholders' equity)
|
12.8%
|
11.3%
|
9.55%
|
12.6%
|
4.93%
|
4.97%
|
ROA (Net income/ Total Assets)
|
-0.02%
|
-0.02%
|
-0.05%
|
-0.03%
|
-0.06%
|
-0.07%
|
Assets
1 |
-1,326,307
|
-1,197,063
|
-517,930
|
-1,367,230
|
-134,550
|
-127,571
|
Book Value Per Share
2 |
52.50
|
59.90
|
62.80
|
73.00
|
39.30
|
40.40
|
Cash Flow per Share
2 |
0.0300
|
0.0100
|
0.0200
|
0.3600
|
0.0200
|
0.0100
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/19
|
2/20/20
|
2/27/21
|
2/26/22
|
3/18/23
|
3/15/24
|
Last Close Price
96.4
EUR Average target price
118.2
EUR Spread / Average Target +22.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.78% | 4.6B | | +26.47% | 664B | | +25.70% | 567B | | -6.33% | 354B | | +19.35% | 330B | | +4.23% | 286B | | +13.42% | 234B | | +4.71% | 199B | | -10.10% | 196B | | -4.04% | 148B |
Other Pharmaceuticals
|